Dupixent (Sanofi/Regeneron), a first-in-class biologic that inhibits IL-4/IL-13 signaling, was approved for the treatment of eosinophilic asthma and oral-corticosteroid-dependent asthma in October…
Dupixent (Sanofi/Regeneron), a first-in-class biologic that inhibits IL-4/IL-13 signaling, was approved for the treatment of eosinophilic asthma and oral-corticosteroid-dependent asthma in October…
Market Outlook Pfizer’s Xeljanz is the first-in-class Jak inhibitor approved for ulcerative colitis (UC) in the United States and the first targeted oral therapy to launch for moderate to severe…
The few currently available pharmacological treatments for opioid addiction fall into one of two categories: substitution therapies or abstinent therapies. Substitution therapies (i.e., methadone,…
MARKET OVERVIEW The narcolepsy market has been characterized by a lack of available and on-label therapies as well as low diagnosis rates because patients often do not seek treatment; however, the…
Celltrion’s Herzuma was the first biosimilar of Roche’s Herceptin, a blockbuster HER2-targeted therapy, to launch in Europe. A few months later, two additional trastuzumab biosimilars launched…
DRG Epidemiology’s coverage of graft versus host disease (GVHD) comprises epidemiological estimates of key patient populations in the emerging pharmaceutical markets (Brazil, China, India, Mexico…
DRG Epidemiology’s coverage of graft versus host disease(GVHD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Current treatment of type 1 diabetes (T1D) consists only of exogenous insulins and Symlin, with Lantus as the patient-share leader in the United States. Intensive insulin regimens have been shown…
Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. Children with CD have a more-complicated…
Market Outlook The migraine prophylaxis therapy market is poised for disruption following the launch of three anti-CGRP MAbs in the United States in 2018, with a fourth in 2020. Amgen / Novartis…
For the estimated 3.4 million people in the United States who suffer from Alzheimer’s disease (AD), approved pharmacotherapy is limited to four procognitive symptomatic agents (e.g., donepezil,…
Market Outlook The migraine prophylaxis therapy market is poised for disruption following the launch of three anti-CGRP MAbs in the United States in 2018, with a fourth in 2020. Amgen / Novartis…
Market Outlook Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum, characterized by diarrhea, abdominal pain, rectal bleeding, fever, and weight…
Market Outlook Chronic inducible urticaria (CIndU) includes different chronic urticaria subtypes that are inducible by specific triggers. Evidence exists that CIndU appears to be more resistant to…
